Cingulate Completes Final FDA Study for CTx-1301 ADHD Treatment
On January 7, 2025, Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD). This study, specifically a food effect study, represents a significant milestone in the development of the drug. The study involved the administration of a single 50mg dose of […]
More Stories
Trump Says Minnesota Officials Will Face ‘Day of Reckoning’ Amid Protests
By Jack Phillips President Donald Trump on Tuesday warned that state officials in Minnesota would face a “DAY OF RECKONING...
US Holiday Spending Jumped in December, Signaling Consumer Strength Into 2026
By Tom Ozimek American consumers closed out the holiday season with a strong December spending surge, adding to evidence that...
US Embassy Warns American Citizens Still in Iran to Leave ‘Now’
By Jack Phillips The U.S. State Department on Monday evening sent a warning to any Americans who are still remaining...
House Panel to Initiate Contempt Proceedings Against Bill Clinton, Comer Says
By Nathan Worcester WASHINGTON—House Oversight Committee Chairman James Comer (R-Ky.) said that his committee will move to hold President Bill...
Pentagon Injects $1 Billion Into L3Harris to Boost Missile Motor Output
By Tom Ozimek The U.S. government will invest $1 billion in L3Harris Technologies’ rocket motor business, a rare direct-to-supplier partnership...
Top Miro Alternatives in 2026 | Free Competitors of Miro for Startups
Looking for an alternative to Miro? Don’t worry, I’ll share a list of tools that are better than Miro. This...